Heated oral arguments at SCOTUS hint at Sanofi-Regeneron edge over Amgen in patent spat
WASHINGTON — Lawyers for Sanofi-Regeneron, Amgen, and the federal government took the stage at the Supreme Court on Monday, arguing a complicated patent case over the two sides’ competing, blockbuster PCSK9 inhibitors with justices’ questions hinting at a decision that will likely be a win for Sanofi and Regeneron.
The morning opened with about 45 minutes for Amgen’s lawyer, Jeffrey Lamken, who was peppered with straightforward questions from Associate Justices Clarence Thomas and Sonia Sotomayor, with Thomas at one point asking, “I’m confused as to what your invention is?”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters